Drug
Umeclidinium
Umeclidinium: highest development phase Post-Market, developed by GlaxoSmithKline. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- GlaxoSmithKline
Trials
| Drug | Phase | Indication |
|---|---|---|
| Umeclidinium NCT02236611 | Post-Market | Pulmonary Disease, Chronic Obstructive |
Latest
No recent events.
Follow Umeclidinium on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.